After more than a year of threats and six months after President Donald Trump signed a national-security proclamation, U.S. tariffs on imported patented medicines and their ingredients expanded Sept. 29 to mid-sized and smaller drugmakers that were left off the first company list. Duties that began July 31 for 17 large manufacturers now apply to…
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
In the U.S. market, generics play a significant role in reducing overall drug spending. The FDA, for instance, estimated that the generics it approved in 2022 alone saved $18.9 billion in their first year on the market. Those savings come out of margins that keep thinning, because generic retail prices are in sustained deflation, as Brookings…
Top pharma companies set sustainability goals, but emissions are still increasing
The health care industry contributes an estimated 4.4% of total global emissions annually. Approximately 71% of this comes from the health care supply chain, which includes the pharmaceutical and biotechnology sectors. Medicines contribute approximately 20% to 55% of health care’s total carbon footprint. This comes from corporate emissions, API production and manufacturing. Pharmaceutical manufacturing is…
Startup vies to get blockchain adoption in pharma off the ground
Blockchain may be arguably one of the most hyped technologies in recent memory, but the distributed ledger technology better known for its role in cryptocurrency may have significant potential in the pharma supply chain, clinical trials and beyond. A blockchain-based initiative known as PharmaLedger has won support from prominent companies like Pfizer, Novartis, Merck &…
4 clinical trial predictions for 2022
The clinical trial space had one of its most significant disruptions in decades in the early days of the pandemic. Now, some clinical trials are normalizing, but decentralized clinical trials are also growing. To learn more about what is likely on the horizon for clinical trials in 2022, we reached out to Jan Pieter Kappelle,…
10 trends that will matter for pharma in 2021
One silver lining of the COVID-19 pandemic is that it has accelerated the rate of change for pharma and life sciences fields in general. The pandemic has forced a rethink of how to manage clinical trials and treat patients in hospitals and their homes. And the breakneck speed of vaccine development in 2020 could potentially…





